Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal for ImmunoTherapy of Cancer

Topics

Biology

Biochemistry

Medicine

Cancer Oncology

Immunology

Show all topics

DOI

10.1186/s40425-018-0356-4

License

CC-BY-NC-ND

Other Formats

PDF